Depot Formulations: One Injection, Months of Peptide
Peptide Delivery
6 months from a single injection
Leuprolide depot (Lupron Depot) delivers a GnRH agonist peptide from PLGA microspheres for up to 6 months from one subcutaneous injection, eliminating daily dosing.
PLGA/PLA depot review, Drug Delivery and Translational Research, 2022
PLGA/PLA depot review, Drug Delivery and Translational Research, 2022
View as imagePeptides are potent but short-lived. An unmodified peptide injected into the body is typically degraded and cleared within minutes to hours. For chronic conditions like prostate cancer, acromegaly, or type 2 diabetes, this means daily or even twice-daily injections. Depot formulations solve this problem by encapsulating the peptide in a material that slowly releases it over weeks or months from a single injection site. The result: one injection replaces 30, 90, or even 180 daily doses.
The technology behind depot formulations is older than most people realize. Lupron Depot (leuprolide acetate in PLGA microspheres) was FDA-approved in 1989. Sandostatin LAR (octreotide in PLGA microspheres) followed in 1998. Today, more than 10 peptide depot products are on the global market, and the underlying technology, primarily based on poly(lactic-co-glycolic acid) or PLGA, has become the most commercially successful peptide delivery platform in pharmaceutical history. For a broader view of microsphere technology for slow-release peptide delivery, the engineering principles are well established but the manufacturing challenges remain formidable.
Key Takeaways
- PLGA microspheres release peptides through a combination of diffusion through pores, polymer erosion, and peptide-polymer interactions over periods from 1 to 6 months
- Lupron Depot (leuprolide) and Sandostatin LAR (octreotide) are the two most commercially successful peptide depot products, both using PLGA microsphere technology approved in the 1980s-90s
- Lanreotide (Somatuline Depot) achieves long-acting release through peptide self-assembly into nanotubes rather than polymer encapsulation, representing a fundamentally different approach (Deghenghi et al., 2001; Jafari et al., 2025)
- Supramolecular nanofiber depots engineered from GLP-1 peptide achieved sustained glucose control without the PLGA polymer, using the peptide itself as the depot matrix (Chen et al., 2024)
- A double-layered PLGA microsphere-dissolving microneedle system achieved sustained peptide release via a painless skin patch rather than injection (Xu et al., 2025)
- Long-acting injectable GLP-1 agonists show equivalent cardiovascular and kidney outcomes to oral formulations, validating the depot approach for metabolic disease (Lee et al., 2025)
How PLGA Microspheres Work
PLGA (poly(lactic-co-glycolic acid)) is a biodegradable copolymer that has been used in medical devices since the 1970s. When a peptide is encapsulated in PLGA microspheres (typically 10-100 micrometers in diameter), it is trapped within a solid polymer matrix. After injection, the microspheres slowly degrade through hydrolysis, releasing the peptide in three phases:
Initial burst release. During the first 24-48 hours, peptide that is loosely associated with the microsphere surface or trapped in surface pores is released rapidly. This burst provides an immediate loading dose but can cause transient side effects. Manufacturing processes aim to minimize burst release while maintaining consistent early drug levels.
Diffusion-controlled phase. Over the following days to weeks, peptide diffuses through water-filled channels and pores in the polymer matrix. The rate depends on pore size, peptide molecular weight, and the hydrophilicity of both the peptide and the polymer. Xu et al. (2025) developed a double-layered microsphere system that creates two distinct diffusion compartments within each particle, producing a more controlled release profile than single-layer designs.[1]
Erosion-controlled phase. As PLGA breaks down into lactic and glycolic acid (both naturally metabolized by the body), the polymer matrix erodes from the surface inward. The degradation rate is determined by the PLGA composition: higher glycolic acid content produces faster degradation (weeks), while higher lactic acid content extends degradation to months. This tunability is what allows manufacturers to create 1-month, 3-month, and 6-month depot products from the same basic technology.
The ratio of lactide to glycolide (L:G ratio) is the primary engineering lever. Lupron Depot uses PLGA 75:25 for its 1-month formulation and adjusts the ratio and molecular weight for its 3- and 6-month versions. Changing this ratio shifts the hydrolysis rate, creating predictable differences in release duration from the same peptide payload.
The FDA-Approved Depot Landscape
The commercial peptide depot market is dominated by a small number of products, most targeting endocrine conditions:
| Product | Peptide | Indication | Duration | Technology |
|---|---|---|---|---|
| Lupron Depot | Leuprolide (GnRH agonist) | Prostate cancer, endometriosis | 1, 3, 4, or 6 months | PLGA microspheres |
| Sandostatin LAR | Octreotide (somatostatin analog) | Acromegaly, NETs | 1 month | PLGA microspheres |
| Somatuline Depot | Lanreotide (somatostatin analog) | Acromegaly, NETs | 1 month | Self-assembling nanotubes |
| Trelstar | Triptorelin (GnRH agonist) | Prostate cancer | 1, 3, or 6 months | PLGA microspheres |
| Bydureon | Exenatide (GLP-1 agonist) | Type 2 diabetes | 1 week | PLGA microspheres |
Deghenghi et al. (2001) characterized the binding properties of the somatostatin octapeptides (lanreotide, octreotide, vapreotide) at both somatostatin and GHRP receptors, establishing the pharmacological basis for their depot formulations. The long-acting versions of these peptides have fundamentally changed how neuroendocrine tumors and acromegaly are managed, replacing daily subcutaneous injections with monthly visits.[2]
Self-Assembling Depots: No Polymer Needed
Lanreotide (Somatuline Depot) represents a fundamentally different depot strategy. Rather than encapsulating the peptide in a polymer, lanreotide molecules spontaneously self-assemble into nanotubes at high concentration. When injected as a supersaturated solution, the peptide forms a gel at the injection site that slowly dissolves over weeks, releasing the active peptide.
Jafari et al. (2025) studied how hydroxypropyl beta-cyclodextrins influence this self-assembly process. The self-assembly of lanreotide is concentration-dependent and can be disrupted or modulated by excipients, which has implications for formulation development and bioavailability. The fact that the peptide itself is the depot eliminates the polymer-related manufacturing complexity and burst release issues associated with PLGA systems.[3]
Chen et al. (2024) extended this concept to GLP-1 therapeutics. They engineered a supramolecular nanofiber depot directly from a GLP-1 peptide analog, designing the peptide sequence to include self-assembling domains that form nanofibers at the injection site. The nanofiber depot achieved sustained glucose control in diabetic mouse models without any PLGA or other synthetic polymer. The peptide served simultaneously as the drug and the delivery vehicle.[4]
This approach, building the depot from the drug itself, is architecturally elegant but limited to peptides whose sequences can accommodate self-assembling motifs without losing pharmacological activity. Not every peptide can be redesigned this way.
Beyond Microspheres: Hydrogels and Microneedles
The PLGA microsphere platform, while commercially dominant, has limitations: manufacturing requires specialized equipment, the double-emulsion process can denature sensitive peptides, and injection through narrow-gauge needles can damage microsphere integrity. Alternative depot technologies are advancing:
Hydrogel depots. Chen et al. (2026) developed a self-assembled charge-complementary hydrogel for sustained antimicrobial peptide release in periodontitis treatment. The hydrogel forms in situ at the injection site, creating a reservoir that releases peptide over weeks. Zattarin et al. (2025) demonstrated a different approach: nanocellulose wound dressings that provide controlled antimicrobial peptide release at infection sites.[5][6]
Peptide hydrogel carriers. Yao et al. (2025) designed short peptide hydrogels with angular structure that encapsulate hydrophobic drugs for controlled release. The peptide backbone provides both the structural framework and the release-controlling matrix, blurring the line between carrier and cargo.[7]
Microneedle patches. Xu et al. (2025) developed a dissolving microneedle patch containing double-layered PLGA microspheres. The microneedles penetrate the outermost skin layer painlessly and dissolve within minutes, depositing the microspheres in the dermal tissue where they release peptide over weeks. This combines the sustained-release advantage of PLGA with the patient-friendly application of a skin patch, eliminating the need for needles entirely.[1]
Nanoparticle-hydrogel combinations. Durak et al. (2026) developed a combined nanoparticle-hydrogel system for sustained release of an anti-VEGF peptide in the eye. The nanoparticles provide initial controlled release while the hydrogel matrix slows diffusion further, creating an extended-release depot for ocular neovascularization treatment that could reduce the frequency of intravitreal injections from monthly to quarterly or beyond.[8]
Clinical Outcomes: Do Depots Match Daily Injections?
The pharmacological question behind every depot is whether slow, continuous peptide release produces the same clinical outcomes as daily bolus dosing. For some peptides, the answer is clearly yes. For others, the kinetics matter.
Lee et al. (2025) conducted meta-analyses comparing long-acting injectable GLP-1 receptor agonists (depot formulations) with oral GLP-1 agonists for cardiovascular and kidney outcomes in type 2 diabetes. Both formulations reduced major adverse cardiovascular events, with no significant difference between injectable depot and oral delivery routes. This validation is important: it confirms that continuous low-level GLP-1 receptor activation from a depot produces equivalent cardiometabolic protection to the intermittent high-level activation from an oral dose.[9]
For GnRH agonists like leuprolide and triptorelin, the depot formulation is actually pharmacologically preferable to daily dosing. These drugs work by initially stimulating and then desensitizing GnRH receptors, achieving chemical castration. The continuous exposure provided by a depot formulation produces more complete receptor desensitization than intermittent daily dosing, making the depot version more effective than the daily version for testosterone suppression in prostate cancer.
Guo et al. (2025) explored a different long-acting approach for peptide receptor radionuclide therapy (PRRT): using an albumin-binding somatostatin analog to extend circulation time. This is not a depot in the traditional sense but achieves a similar goal of prolonged peptide exposure through protein binding rather than polymer encapsulation.[10]
The connection between depot technology and lipidation strategies for extending peptide half-life and PEGylation approaches reflects a shared goal: making peptides last longer in the body. Depots achieve this through controlled release from a reservoir; lipidation and PEGylation achieve it by slowing clearance of the circulating peptide. The optimal strategy depends on the peptide's pharmacology, the disease, and the patient's tolerance for injection frequency.
For subcutaneous peptide injection specifically, the depot approach transforms the injection site from a transient absorption point into a long-term drug reservoir.
Manufacturing Challenges and the Generic Gap
Despite PLGA's long regulatory history, manufacturing peptide-loaded microspheres at commercial scale remains technically demanding. The double-emulsion solvent evaporation process, used for most PLGA microspheres, requires precise control of temperature, stirring speed, solvent ratios, and emulsifier concentrations. Small deviations produce batch-to-batch variability in particle size, drug loading, porosity, and release kinetics. Each of these variables directly affects the clinical performance of the product.
This manufacturing complexity explains why generic versions of peptide depots have been slow to reach the market. The FDA requires generic depot products to demonstrate equivalent in vitro release profiles and equivalent in vivo pharmacokinetics, but reproducing the exact microstructure of a branded microsphere product is difficult without access to the originator's proprietary process parameters. Lupron Depot faced no generic competition for over 25 years after its original approval.
The challenge extends to storage and handling. PLGA microsphere products must be stored at controlled temperatures (typically 2-8 degrees Celsius) and reconstituted immediately before injection. The reconstitution step itself is a source of variability: if the microspheres are not uniformly suspended before injection, the patient receives a non-representative sample of the batch, leading to unpredictable drug levels.
Peptide stability within the microsphere is another concern. During encapsulation, peptides are exposed to organic solvents, high shear forces, and acidic microenvironments as PLGA degrades. These conditions can cause acylation, aggregation, or deamidation of the peptide, producing degradation products that reduce potency and may cause immunogenicity. Octreotide, for example, forms acyl adducts with PLGA acid end groups, a reaction that both reduces the amount of active peptide available and paradoxically extends the release profile beyond what erosion alone would predict.
Patient Adherence and Quality of Life
The clinical case for depot formulations extends beyond pharmacokinetics. Adherence to daily injectable peptide regimens is poor. Studies of daily somatostatin analog injections for acromegaly reported adherence rates as low as 50-60% over 12 months. Monthly depot injections, administered in a clinical setting, achieve near-100% adherence by design: the patient cannot miss a dose because the drug is already in their body.
For oncology indications, adherence is potentially life-or-death. A patient who inconsistently takes daily leuprolide for prostate cancer may experience testosterone surges that fuel tumor growth. The 6-month depot formulation eliminates this risk entirely, providing uninterrupted testosterone suppression with two injections per year.
The trade-off is flexibility. If a patient experiences intolerable side effects from a depot formulation, the drug cannot be discontinued; it will continue releasing for weeks or months. With daily injections, the patient simply stops taking the drug and side effects resolve as the peptide clears. This irreversibility of depot dosing requires more careful patient selection and counseling before initiation.
The emerging microneedle patch approach may change this calculus. A depot delivered through a skin patch could theoretically be removed if adverse effects develop, though whether microspheres already deposited in dermal tissue could be effectively extracted remains untested. The frictionless application of a patch also eliminates the needle phobia that deters some patients from injectable depot products, potentially broadening the eligible patient population. For pediatric and geriatric populations especially, the shift from a monthly intramuscular injection to a painless patch would represent a qualitative improvement in the treatment experience.
The Bottom Line
Depot formulations have transformed peptide therapeutics by converting daily injections into monthly or semi-annual dosing. PLGA microsphere technology dominates the market with products like Lupron Depot and Sandostatin LAR, releasing peptides through diffusion and polymer erosion. Self-assembling depots (lanreotide nanotubes, GLP-1 nanofibers) eliminate the polymer entirely. Emerging technologies including dissolving microneedle patches, hydrogel depots, and nanoparticle-hydrogel combinations are expanding the depot toolkit beyond injectable microspheres. Clinical outcomes data confirms that depot formulations match or exceed daily dosing for cardiovascular, endocrine, and oncological endpoints.